Featured Research

from universities, journals, and other organizations

University Of Illinois At Chicago Study Identifies Possible Predictor Of Tamoxifen Resistance

Date:
May 9, 2003
Source:
University Of Illinois At Chicago
Summary:
A discovery from the University of Illinois at Chicago College of Pharmacy may make it possible to anticipate which breast cancer patients will respond to tamoxifen and to devise a more appropriate therapy for those who do not.

A discovery from the University of Illinois at Chicago College of Pharmacy may make it possible to anticipate which breast cancer patients will respond to tamoxifen and to devise a more appropriate therapy for those who do not.

Tamoxifen has been used for more than 25 years to treat patients with certain types of breast cancer. But the drug is not effective for all patients, and until now, doctors and researchers have been unable to predict who would benefit and why.

In an article in the current issue of the British Journal of Cancer, Debra Tonetti, assistant professor of biopharmaceutical sciences in the UIC College of Pharmacy, reports the results of a study that identifies a possible predictor of tamoxifen resistance.

Tamoxifen works by blocking the effect of estrogen, which promotes the growth of breast cancer cells containing the estrogen receptor. However, in a retrospective study, Tonetti found that patients whose disease recurred had high levels of an enzyme called protein kinase C alpha, whereas patients who remained disease-free for at least five years had very low levels of PKC-alpha or none at all.

"Overproduction of PKC-alpha may be used to predict who will not respond to tamoxifen," Tonetti said. "In addition, we found that in mice, tumors that overproduce PKC-alpha completely regress with estrogen treatment."

These findings, her paper states, "may have important therapeutic applications in the management of breast cancer patients."

The initial study used archival biopsied tissue from 30 patients. Tonetti is now expanding her study, funded in part by the National Cancer Institute, and will use tissue from several hundred patients matched by age and disease stage to substantiate the preliminary findings. Upon completion of the entire study, in about 18 months, she hopes to start clinical trials.

"Cancer recurrence is a real problem," she said. "Finding more effective strategies for treating it would be very helpful."

For more information on the UIC College of Pharmacy, visit http://www.uic.edu/pharmacy.


Story Source:

The above story is based on materials provided by University Of Illinois At Chicago. Note: Materials may be edited for content and length.


Cite This Page:

University Of Illinois At Chicago. "University Of Illinois At Chicago Study Identifies Possible Predictor Of Tamoxifen Resistance." ScienceDaily. ScienceDaily, 9 May 2003. <www.sciencedaily.com/releases/2003/05/030509084441.htm>.
University Of Illinois At Chicago. (2003, May 9). University Of Illinois At Chicago Study Identifies Possible Predictor Of Tamoxifen Resistance. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2003/05/030509084441.htm
University Of Illinois At Chicago. "University Of Illinois At Chicago Study Identifies Possible Predictor Of Tamoxifen Resistance." ScienceDaily. www.sciencedaily.com/releases/2003/05/030509084441.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins